Hypha Labs Reports Net Loss of $562,023 for Quarter Ending June 30, 2025

Hypha Labs, Inc. reported its financial results for the three and nine months ended June 30, 2025, revealing a net loss of $562,023 for the quarter and $2,543,486 for the nine-month period. The company did not generate any revenue during these periods, consistent with its transition away from its previous operations as a cannabis testing laboratory following the sale of its subsidiary, Digipath Labs, in February 2024. This marks a significant shift from the prior year, where the company reported a net loss of $706,897 for the same quarter and a net loss of $319,430 for the nine months ended June 30, 2024.

Operating expenses for the three months ended June 30, 2025, totaled $536,027, a decrease from $613,573 in the same period last year. This decline was primarily driven by a significant reduction in general and administrative expenses, which fell by 83% to $81,683. However, professional fees surged by 257% to $454,344, largely due to increased corporate consulting and legal fees associated with the development of new business initiatives. For the nine-month period, total operating expenses rose to $2,510,453, compared to $1,258,184 in the previous year, reflecting increased corporate overhead and stock-based compensation.

Hypha Labs has undergone strategic changes, including the formation of Hypha Products Inc. in April 2024, which is focused on the development and commercialization of the Hypha Micropearl accelerator. This home appliance aims to facilitate the production of nutritionally beneficial mushrooms for human consumption. The company plans to continue testing and developing this product over the next six months, with an eye toward a potential market launch by the end of 2025, although this timeline is subject to change.

Operationally, the company reported a cash balance of $147,192 as of June 30, 2025, down from $509,028 a year earlier. The company also reported negative working capital of $1,846,324 and an accumulated deficit of $23,090,912, raising concerns about its ability to continue as a going concern. Hypha Labs intends to seek additional funding through equity or debt securities to support the development and launch of its new product, as well as to explore potential acquisition targets.

Looking ahead, Hypha Labs faces significant challenges, including the need to secure funding and successfully transition to its new business model. The company has acknowledged the uncertainty surrounding its ability to achieve profitability and sustain operations without further financing. The management's forward-looking statements emphasize the importance of raising capital to execute its business plan effectively.